Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Debu Tripathy, editor-in-chief of CURE magazine, reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer. Two trials called SOFT and TEXT were combined and long-term follow-up results were announced at the San Antonio Breast Cancer Symposium. In the combined results, certain groups of patients, but not all, did seem to receive a benefit with tamoxifen in addition to shutting down the ovaries.
"This is an important conversation for patients to have when they are completing their therapy if their tumor is hormone-sensitive, and they're going to be getting hormone therapy and they're pre-menopausal (they're still having their periods)," he says. "For some patients, this may help."
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Listen
Teddi Mellencamp Reveals More Melanoma Lesions, Michael Strahan’s Daughter Cancer-Free and More
July 19th 2024From Teddi Mellencamp revealing that she had more melanoma spots removed to Isabella Strahan announcing being cancer-free, here’s what’s happening in the oncology space this week.
Read More